Revestive subcutaneous injection 0.95mg, manufactured by Takeda Pharmaceutical, contains Teduglutide (genetical recombination). This medicine is an analog of glucagon-like peptide-2 (GLP-2) used to treat short bowel syndrome. It is provided as a 0.95mg 1 bottle (with dissolving solution) with YJ code 2499419D2022.
Revestive subcutaneous injection 0.95mg
Need more detailed information?
Contact TASAKI PHARMA for inquiries about this medicine (English support available).
Contact us about this drug →